R
Ronald Nahass
Researcher at Rutgers University
Publications - 44
Citations - 3156
Ronald Nahass is an academic researcher from Rutgers University. The author has contributed to research in topics: Sofosbuvir & Medicine. The author has an hindex of 17, co-authored 34 publications receiving 2951 citations. Previous affiliations of Ronald Nahass include Robert Wood Johnson University Hospital.
Papers
More filters
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal,K. Rajender Reddy,David R. Nelson,Eric Lawitz,Stuart C. Gordon,Eugene R. Schiff,Ronald Nahass,Reem Ghalib,Norman Gitlin,Robert Herring,Jacob Lalezari,Ziad Younes,Paul J. Pockros,Adrian M. Di Bisceglie,Sanjeev Arora,G. Mani Subramanian,Yanni Zhu,Hadas Dvory-Sobol,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Mark S. Sulkowski,Paul Y. Kwo +24 more
TL;DR: Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologyic response to prior interferon-based treatment.
Journal Article
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
Gregory J. Dore,Frederick L. Altice,Alain H. Litwin,Olav Dalgard,Edward Gane,Oren Shibolet,Anne F Luetkemeyer,Ronald Nahass,Cheng Yuan Peng,Brian Conway,Jason Grebely,Anita Y. M. Howe,I.N. Gendrano,Erluo Chen,H.-C. Huang,Frank J. Dutko,David C. Nickle,Bach-Yen Nguyen,Janice Wahl,Eliav Barr,Michael N. Robertson,Heather L. Platt +21 more
TL;DR: Patients with HCV infection who were receiving OAT and treated with elbasvir-grazoprevir had high rates of SVR12, regardless of ongoing drug use, and these results support the removal of drug use as a barrier to interferon-free HCV treatment for patients receiving Oat.
Journal ArticleDOI
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Gregory J. Dore,Frederick L. Altice,Alain H. Litwin,Olav Dalgard,Edward Gane,Oren Shibolet,Anne F Luetkemeyer,Ronald Nahass,Cheng Yuan Peng,Brian Conway,Jason Grebely,Anita Y. M. Howe,I.N. Gendrano,Erluo Chen,Hsueh Cheng Huang,Frank J. Dutko,David C. Nickle,Bach-Yen Nguyen,Janice Wahl,Eliav Barr,Michael N. Robertson,Heather L. Platt +21 more
TL;DR: In this paper, the authors evaluated elbasvir-grazoprevir in treating HCV infection in persons who inject drugs (PWID), and the primary outcome was sustained virologic response at 12 weeks (SVR12), evaluated separately in the ITG and DTG.
Journal ArticleDOI
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark S. Sulkowski,Christophe Hézode,Jan Gerstoft,John M. Vierling,Josep Mallolas,Stanislas Pol,Marcelo Kugelmas,Abel Murillo,Nina Weis,Ronald Nahass,Oren Shibolet,Lawrence Serfaty,Marc Bourlière,Edwin DeJesus,Eli Zuckerman,Frank J. Dutko,Melissa Shaughnessy,Peggy Hwang,Anita Y. M. Howe,Janice Wahl,Michael N. Robertson,Eliav Barr,Barbara Haber +22 more
TL;DR: The C-WORTHY trial as mentioned in this paper evaluated the efficacy and safety of a combination of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) mono-infection and co-infected patients.
Journal ArticleDOI
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
Graham R. Foster,Stephen Pianko,Ashley Brown,Daniel M. Forton,Ronald Nahass,Jacob George,Eleanor Barnes,Diana M. Brainard,Benedetta Massetto,Ming Lin,Bin Han,John G. McHutchison,G. Mani Subramanian,Curtis Cooper,Kosh Agarwal +14 more
TL;DR: Among patients with genotype 3 HCV infection, including a large proportion of treatment-experienced patients with cirrhosis, the combination of sofosbuvir, peginterferon, and ribavirin for 12 weeks produces high rates of SVR.